Sopharma AD notifies that for November 2014 the Company recorded a decrease of sales revenues of 7% compared to the same month of 2013, including 4% increase of domestic sales and 11% decrease of export sales. During the past eleven months Sopharma AD recorded a decrease of sales revenues of 4%, including 4% increase of domestic sales and 7% decrease of export sales compared to the same period of 2013.

SOPHARMA AD hereby informs that from 4 December 2014 up to and including 10 December 2014 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, to the total value of 796 BGN on the Bulgarian Stock Exchange, the average price per share was 3.98 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 113 043, representing 3.87% of the share capital of the Company.

SOPHARMA AD hereby informs that from 11 December 2014 up to and including 17 December 2014 the Company bought 510 own shares representing 0.00039% of the share capital of the Company, to the total value of 1964.01 BGN on the Bulgarian Stock Exchange, the average price per share was 3.85 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 113 553, representing 3.87% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that on the regular General Meeting of Shareholders of Sopharma AD, conducted on 20 June 2014 in Sofia, 5 Lachezar Stanchev Str., were taken the following decisions:

Sopharma AD (the “Company”) notifies that for December 2013 the Company recorded an increase of sales revenues of 63% compared to the same period of 2012, including 31% increase of domestic sales and 102% increase of export sales.

During the past year Sopharma AD recorded an increase of sales revenues of 3%, including 7% increase of domestic sales and 1% increase of export sales compared to 2012.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 5 September 2012 up to and including 12 September 2012 the Company bought 100 own shares representing 0.000076% of the share capital of the Company, to the total value of BGN 241.00 on the Bulgarian Stock Exchange. The average price per share was BGN 2.41.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that between 29 August 2012 and 05 September 2012, including, the Company bought back 18746 own shares representing 0.0142% of the share capital of the Company, at a total value of BGN 45675.09 on the Bulgarian Stock Exchange. The average price per share was BGN 2.44.

The shares have been bought on the basis of the decision of the General Meeting of Shareholders from 23 June 2010.

We would like to notify that for the month of August 2012 "Sopharma" AD recorded a decline in sales of 6% compared to the same month of the previous year, including an 8% drop in export sales and a 1% increase in domestic sales.

Revenue from sales in the first eight months of the current year rose by 2%, including a 10% decline for the domestic market and an 8% increase in exports compared to the same period in 2011.

The Board of Directors of Sopharma AD (the “Company”) presents the Invitation and the materials for the Extraordinary General Meeting of shareholders of "Sopharma” AD, which shall take place on 1 November 2012 from 11.00 AM and, in the absence of a quorum - on 15 November 2012 from 11.00 AM in Sofia, "Iliensko shosee" No 16.

Attachments:

1.Invitation to EGM;
2.Minutes of the meeting of the Board of Directors for the convening of EGM
3.Sample letter of attorney for EGM

Sopharma AD notifies that for December 2014 the Company recorded a decrease of sales revenues of 29% compared to the same month of 2013, including 20% decrease of domestic sales and 36% decrease of export sales.

During the past year Sopharma AD recorded a decrease of sales revenues of 7%, including 1% increase of domestic sales and 10% decrease of export sales compared to 2013.